Tracking the impact of biosimilars

Biosimilars make up almost
25% of spend

In spaces where there is an originator biologic, biosimilars now make up almost 25% of spend. Find out when — and why — we expect to see the impact of biosimilar adalimumab and other biologics on pharmaceutical spend in our latest forecast.


Projected overall drug price inflation rate for Jan. 1 – Dec. 31, 2024

Gain access now

Plan for 2024 with our new projections and insights. Download the latest drug budget forecasts to inform your pharmacy planning.

Gain actionable insights from our new report.

Access the report

Pharmacy program participants

Enjoy exclusive access to companion resources and additional information

Price change projections at the individual medication level by generic drug name and by therapeutic class.

Access detailed price projections
A high-level overview and highlights from the Pharmacy Market Outlook.

Read the executive summary
Includes an overview of 340B program challenges, non-acute growth and a pharmacy enterprise non-acute preparedness assessment.

Read and share the letter to the C-suite
Forecasted timetable for new drug approvals, regulatory and accreditation events as well as the anticipated availability of new generics and biosimilars.

Access the forecasted timetable and approvals
Key market segment highlights including top spend drugs and current trends.

Access now
Summaries from key therapeutic classes including autoimmune and chronic inflammatory diseases, biosimilars, cardiometabolic diseases, neurology and more. Includes top spend drugs, projected inflation rates and trends for each therapeutic class.

Access now
Pediatric hospitals have big budgetary and ethical challenges coming with the growth of the gene and cell therapy pipeline. Learn more including the projected inflation rate for 2024.

Read about upcoming changes
Upcoming operational and regulatory topics — Find out about upcoming operational and regulatory updates including Drug Supply Chain Security Act (DSCSA) requirements for enhanced drug distribution security.

Advocacy in action — Numerous aspects of pharmaceutical policy and pharmacy practice remain the subject of existing bills, laws and regulations regarding safety, quality, and of course, cost. Read about our advocacy efforts concerning some of the most critical policy issues covered in the first half of 2023, as well as areas requiring scrutiny in the near term.
Access the Drug Budget Forecast Report and apply the projections in the Pharmacy Market Outlook to your unique purchasing patterns to develop your 2024 plan. This tool is available in the Vizient Savings Actualyzer for Pharmacy platform.

Find out how to use the report. This guide provides an overview on how to best utilize and optimize the Drug Budget Forecast reporting solution.
Oct. 4, 1 p.m. CT

Experts will provide insights into advancements in oncology therapy including CAR-T, new drug approvals and other topics. Additionally, we will discuss practice challenges related to current drug shortages of generic injectable cancer agents.

Register now
Oct. 25, 1 p.m. CT

During this session, pharmacy experts will provide insights about operationalizing specialty medications from the payer and provider perspectives. We will discuss general best practices as well as specific drugs and what factors to consider regarding biosimilar adoption.

Register now